Tests a heart-lung support device in children with severe heart failure
Tests a heart-lung support device and two blood thinners in children with heart failure.
Key facts
- Who runs it
- Stanford University
- Where
- Dallas, Durham, New York, Palo Alto, and Seattle, United StatesSee the 5 sites
- Trial code
- Registry title
- Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 50 people, planned
- Started
- 15 Apr 2025
- Expected to end
- Sept 2029
- Type of study
- Interventional, 2 groups
- Treatments tested
- Cardiohelp device (VA-ECMO)
- Heparin
- Bivalirudin
- Record updated
- 10 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children aged 0 to 16 years with severe heart failure who are on heart-lung support (VA-ECMO) with the Cardiohelp system for the first time during this hospital stay.
- Age
- 0 to 16 years (under 17).
- Sex
- All sexes can join.
- Disease stage
- Severe heart failure needing VA-ECMO (heart-lung support) because the heart itself has failed. Body weight must be 2.5 to 80 kilograms (6–176 lb (3–80 kg)).
- Earlier treatment
- This must be the first ECMO run during the current hospital stay, using the Cardiohelp system.
Main reasons for not taking part
- Bleeding or a clotting problem that makes blood thinners unsafe
- Irreversible kidney, liver or lung failure
- Stroke or unclear brain status within the past 30 days
- ECMO for lung failure, VV-ECMO, or an ECMO system other than the Cardiohelp
- Pregnant or breastfeeding
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Age 0 to 16 years of age (i.e., <17 years)
- Body weight 2.5 to 80 kilograms
- VA-ECMO use for primary cardiac failure using the Cardiohelp system
- First ECMO run during the current hospitalization
- Written informed consent from the parent or legally appointed representative (LAR)
Who cannot take part
- Allergy or contraindication to receiving UFH or bivalirudin as a primary anticoagulant on ECMO
- Bleeding or coagulopathy that is a contraindication to anticoagulation
- Irreversible renal, hepatic or lung failure
- Stroke or uncertain neurological status within the past 30 days
- VV-ECMO or ECMO for primary respiratory failure
- Failure to separate from cardiopulmonary bypass
- Gestationally-corrected age <37 weeks
- Severely malnourished
- Use of an ECMO system other than the Cardiohelp
- Goals of patient to focus on comfort measures only
- Patients who are pregnant or breastfeeding
- Unable to undergo randomization within 30 hours following ECMO cannulation (randomized cohort only)
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 0 and 16 years old?
Where in United States
- Children's Health DallasDallas, United StatesContact: Sirine Baltagi, MDTaking people
- Duke University HospitalDurham, United StatesContact: Caroline Ozment, MDTaking people
- Cuimc/NyphNew York, United StatesContact: Eva Cheung, MDTaking people
- Lucile Packard Children's HospitalPalo Alto, United StatesContact: Kate Ryan, MDTaking people
- Seattle Children's HospitalSeattle, United StatesContact: Michael McMullan, MDTaking people
About the trial
What the trial wants to find out
There are two primary goals of this multicenter clinical trial that combines an FDA device trial and a phase II drug trial in the same study cohort. These two goals are to:
Read full original descriptionShow less
1. To evaluate the safety and effectiveness of the Cardiohelp Device for VA-ECMO (heart-lung support) for up to 30 days of support in children with severe heart failure with the goal to support its FDA clearance in children. 2. To evaluate heparin versus bivalirudin as the primary blood thinner (anticoagulant) in a randomized trial of children supported with the Cardiohelp ECMO System with the goal to plan a phase III (pivotal) randomized clinical trial
The main questions the Cardiohelp single-arm trial seeks to answer are:
* What is the safety and effectiveness of the Cardiohelp device for pediatric ECMO? * Should the Cardiohelp device be FDA-cleared for children based on the results of the study? * What are the optimal performance specifications of the Cardiohelp device in children?
The main questions the blood thinner randomized trial seeks to answer are:
* Which blood thinner is more promising (i.e., more effective and safer) in children on the Cardiohelp device? * How should a pivotal trial of heparin vs. bivalirudin be designed so it is the most informative and efficient to determine the best blood thinner?
Children who are receiving the Cardiohelp device will be approached and consented to participate if interested. For the Cardiohelp device trial, participants will undergo a standardized data collection to estimate survival to 30 days and the prevalence of serious adverse events like stroke, bleeding, and hemolysis. For the blood thinner randomized trial, participants will be randomized 1:1 to blood thinner strategy to determine which blood thinner has the fewest bleeding and clotting complications.
For the Cardiohelp single-arm trial, participant outcomes will be compared to performance goals (PG) derived from the ECMO literature. For the blood thinner randomized trial, the amount of bleeding and clotting will be measured.
The study is funded by an R01 grant from the FDA's Office of Orphan Product Development (OOPD).
The 2 groups in the trial
- Cardiohelp device managed according to a standardized guideline using heparin anticoagulationTreatment being tested
Participants receiving the Cardiohelp device for severe heart failure will be managed according to a standardized treatment guideline (equipment, monitoring, etc.) where heparin is the primary blood thinner to estimate the safety and effectiveness of the device and blood thinner strategy for up to 30 days of support.
Treatment: Cardiohelp device (VA-ECMO) and Heparin
- Cardiohelp device managed according to a standardized guideline using bivalirudin anticoagulationTreatment being tested
Participants receiving the Cardiohelp device for severe heart failure will be managed according to a standardized treatment guideline (equipment, monitoring, etc.) where bivalirudin is the primary blood thinner to estimate the safety and effectiveness of the device and blood thinner strategy for up to 30 days of support.
Treatment: Cardiohelp device (VA-ECMO) and Bivalirudin
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Multicenter Trial to Evaluate the Safety and Effectiveness of the Cardiohelp System for up to 30 Days of Support in Children With Severe Cardiac Failure
- Plain-language title
- Tests a heart-lung support device in children with severe heart failureGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06080074, who can take part
- Record updated
- 10 August 2026